New Phase 3 Clinical Trial for Hyperinsulinism Drug
The upLIFT study, phase 3 clinical trial of ersodetug for tumour hyperinsulinism (HI), a drug from Rezolute (a late-stage rare disease company) is now enrolling participants through 2 UK centres.
Click to learn more